Dr. Lal PathLabs Limited
NSE: LALPATHLAB BSE: LALPATHLAB
Prev Close
2714.1
Open Price
2694
Volume
65,169
Today Low / High
2694 / 2744.6
52 WK Low / High
2201.2 / 3653.95
Range
2,591 - 2,864
Prev Close
2708.8
Open Price
2724.95
Volume
1,321
Today Low / High
2694.4 / 2745.85
52 WK Low / High
2210 / 3645
Range
2,592 - 2,865
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 2727.2 (target range: 2,591 - 2,864), reflecting a change of 13.1 (0.48266%). On the BSE, it is listed at 2728.35 (target range: 2,592 - 2,865), showing a change of 19.55 (0.72172%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Dr. Lal PathLabs Limited Graph
Dr. Lal PathLabs Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Dr. Lal PathLabs Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 2,727.20, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 2,728.35 | 2,755.63 | 2,480.07 - 3,031.20 |
| 2,782.92 | 2,226.33 - 3,339.50 | ||
| 2,810.20 | 1,967.14 - 3,653.26 | ||
| Bearish Scenario | 2,728.35 | 2,701.07 | 2,430.96 - 2,971.17 |
| 2,673.78 | 2,139.03 - 3,208.54 | ||
| 2,646.50 | 1,852.55 - 3,440.45 |
Overview of Dr. Lal PathLabs Limited
ISIN
INE600L01024
Industry
Medical - Diagnostics & Research
Vol.Avg
220,684
Market Cap
227,249,424,399
Last Dividend
24
Official Website
IPO Date
2015-12-23
DCF Diff
-3,064.35
DCF
5,790
Financial Ratios Every Investor Needs
Stock Dividend of LALPATHLAB
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-02-05 | February 05, 25 | 6 | 6 | 2025-02-05 | 2025-03-01 | |
| 2024-11-05 | November 05, 24 | 6 | 6 | 2024-11-05 | 2024-11-22 | |
| 2024-08-20 | August 20, 24 | 6 | 6 | 2024-08-20 | 2024-09-06 | |
| 2024-06-10 | June 10, 24 | 6 | 6 | 2024-06-10 | 2024-07-29 | |
| 2024-02-13 | February 13, 24 | 12 | 12 | 2024-02-13 | 2024-03-02 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 2,226.64 Cr | 947.61 Cr | 1,279.03 Cr | 0.5744 | 0.00 Cr | 122.27 Cr | 865.50 Cr | 357.74 Cr | 43.05 | 678.15 Cr | 0.1607 |
| 2023-03-31 | 2,016.90 Cr | 447.20 Cr | 1,569.70 Cr | 0.7783 | 3.60 Cr | 282.03 Cr | 340.15 Cr | 238.85 Cr | 28.82 | 531.55 Cr | 0.1184 |
| 2022-03-31 | 2,087.28 Cr | 786.79 Cr | 1,300.49 Cr | 0.6231 | 3.39 Cr | 131.02 Cr | 454.71 Cr | 344.80 Cr | 41.70 | 613.26 Cr | 0.1652 |
| 2021-03-31 | 1,581.27 Cr | 397.26 Cr | 1,184.01 Cr | 0.7488 | 0.00 Cr | 87.17 Cr | 359.78 Cr | 291.62 Cr | 35.33 | 487.58 Cr | 0.1844 |
| 2020-03-31 | 1,330.36 Cr | 298.70 Cr | 1,031.65 Cr | 0.7755 | 0.00 Cr | 86.23 Cr | 270.91 Cr | 225.94 Cr | 27.42 | 398.61 Cr | 0.1698 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 360.93 Cr | 2,455.96 Cr | 570.60 Cr | 1,849.2830 Cr | 246.93 Cr | -114.00 Cr | 37.31 Cr | 346.98 Cr | 22.48 Cr | 0.00 Cr | 65.40 Cr | 465.1880 Cr |
| 2023-03-31 | 263.70 Cr | 2,385.50 Cr | 686.00 Cr | 1,666.3000 Cr | 419.50 Cr | 155.80 Cr | 33.80 Cr | 404.00 Cr | 75.90 Cr | 83.33 Cr | -547.20 Cr | 469.8000 Cr |
| 2022-03-31 | 378.20 Cr | 2,353.22 Cr | 809.68 Cr | 1,508.0770 Cr | 532.44 Cr | 154.24 Cr | 52.54 Cr | 444.85 Cr | 91.10 Cr | 166.93 Cr | -315.30 Cr | 499.9880 Cr |
| 2021-03-31 | 244.30 Cr | 1,661.33 Cr | 385.32 Cr | 1,245.0590 Cr | 150.37 Cr | -93.93 Cr | 42.56 Cr | 317.62 Cr | 66.25 Cr | 0.24 Cr | -735.75 Cr | 274.2850 Cr |
| 2020-03-31 | 196.72 Cr | 1,374.31 Cr | 320.28 Cr | 1,032.8080 Cr | 129.37 Cr | -67.35 Cr | 56.96 Cr | 302.10 Cr | 67.05 Cr | 0.00 Cr | -521.11 Cr | 227.3070 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 535.3340 Cr | -24.2690 Cr | -413.8630 Cr | 477.9000 Cr | 97.2020 Cr | 360.9330 Cr | -51.1670 Cr | 357.7350 Cr | -153.3370 Cr | -201.1690 Cr | -3.5000 Cr |
| 2023-03-31 | 456.0000 Cr | -287.3000 Cr | -283.2000 Cr | 411.4000 Cr | -114.5000 Cr | 263.7000 Cr | -44.6000 Cr | 241.1000 Cr | -143.1760 Cr | -103.0130 Cr | 18.7000 Cr |
| 2022-03-31 | 446.6940 Cr | -449.2470 Cr | 136.4510 Cr | -29.4490 Cr | 133.8970 Cr | 378.1950 Cr | -476.1430 Cr | 350.2910 Cr | 345.4000 Cr | -116.6600 Cr | -9.9830 Cr |
| 2021-03-31 | 398.1500 Cr | -212.0160 Cr | -138.5560 Cr | 338.5600 Cr | 47.5780 Cr | 244.2980 Cr | -59.5900 Cr | 296.4790 Cr | -23.5270 Cr | -99.4830 Cr | 14.4020 Cr |
| 2020-03-31 | 283.8900 Cr | -26.1140 Cr | -190.4450 Cr | 204.2730 Cr | 67.3310 Cr | 196.7180 Cr | -79.6170 Cr | 227.5870 Cr | 0.0000 Cr | -155.5020 Cr | -28.4250 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 596.70 Cr | 203.70 Cr | 393.00 Cr | 0.6586 | 118.50 Cr | 96.70 Cr | 11.60 | 179.10 Cr | 0.1621 |
| 2024-09-30 | 660.20 Cr | 380.30 Cr | 279.90 Cr | 0.4240 | 167.20 Cr | 129.20 Cr | 15.52 | 224.40 Cr | 0.1957 |
| 2024-06-30 | 601.90 Cr | 354.40 Cr | 247.50 Cr | 0.4112 | 135.30 Cr | 106.40 Cr | 12.78 | 190.60 Cr | 0.1768 |
| 2024-03-31 | 545.40 Cr | 326.50 Cr | 218.90 Cr | 0.4014 | 108.10 Cr | 84.54 Cr | 10.13 | 163.10 Cr | 0.1550 |
| 2023-12-31 | 538.90 Cr | 184.70 Cr | 354.20 Cr | 0.6573 | 122.90 Cr | 81.30 Cr | 9.77 | 158.90 Cr | 0.1509 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 106.80 Cr | 1,053.90 Cr | 1,160.70 Cr | 0.00 Cr | 46.80 Cr | 1,325.60 Cr | 329.10 Cr | 2,597.50 Cr | 562.30 Cr |
| 2024-06-30 | -942.60 Cr | 1,885.19 Cr | 942.60 Cr | 0.00 Cr | 0.00 Cr | 942.60 Cr | 0.00 Cr | 0.00 Cr | -1,885.36 Cr |
| 2024-03-31 | 830.30 Cr | 113.80 Cr | 944.10 Cr | 77.40 Cr | 37.30 Cr | 1,126.70 Cr | 347.00 Cr | 2,456.00 Cr | 570.60 Cr |
| 2023-12-31 | -896.80 Cr | 1,793.60 Cr | 896.80 Cr | 0.00 Cr | 0.00 Cr | 896.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 120.00 Cr | 809.50 Cr | 929.50 Cr | 85.50 Cr | 40.90 Cr | 1,078.80 Cr | 356.80 Cr | 2,445.30 Cr | 639.20 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 106.40 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 84.54 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 81.30 Cr | 72.00 Cr | 0.00 Cr | 0.00 Cr | 72.00 Cr | 858.40 Cr | 786.40 Cr | 0.00 Cr | 72.00 Cr |
| 2023-09-30 | 109.30 Cr | 71.80 Cr | 0.00 Cr | 0.00 Cr | 71.80 Cr | 786.40 Cr | 714.60 Cr | 0.00 Cr | 71.80 Cr |
| 2023-06-30 | 82.60 Cr | 70.20 Cr | 0.00 Cr | 0.00 Cr | 70.20 Cr | 334.98 Cr | 264.78 Cr | 0.00 Cr | 70.20 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Medical - Diagnostics & Research
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Dr. Lal PathLabs Limited | LALPATHLAB | ₹2,727.20 | ₹227,249,424,399.00 | ₹65,169.00 |
| Vijaya Diagnostic Centre Limited | VIJAYA | ₹1,100.20 | ₹112,920,435,256.00 | ₹1,846,084.00 |
| Metropolis Healthcare Limited | METROPOLIS | ₹1,700.90 | ₹87,224,063,812.00 | ₹80,914.00 |
| Thyrocare Technologies Limited | THYROCARE | ₹731.00 | ₹38,738,211,950.00 | ₹37,171.00 |
| Krsnaa Diagnostics Limited | KRSNAA | ₹809.25 | ₹26,130,490,708.00 | ₹73,440.00 |
Key Executives
Gender: male
Year Born:
Gender: male
Year Born:
Gender: Not Specified
Year Born: 1956
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1969
Gender: male
Year Born:
Gender: Not Specified
Year Born: 1949
FAQs about Dr. Lal PathLabs Limited
The CEO is Mr. Shankha Banerjee.
The current price is ₹2,727.20.
The range is ₹2201.2-3653.95.
The market capitalization is ₹22,724.94 crores.
The dividend yield is 0.88%.
The P/E ratio is 54.54.
The company operates in the Healthcare sector.
Overview of Dr. Lal PathLabs Limited (ISIN: INE600L01024) is a leading Medical - Diagnostics & Research in India. With a market capitalization of ₹22,724.94 crores and an average daily volume of 220,684 shares, it operates in the Medical - Diagnostics & Research. The company last declared a dividend of ₹24.